Considerations for anti‐<scp>PD1</scp>‐based first‐line treatment of Hodgkin lymphoma-Reference-Cited by-同舟云学术

Considerations for anti‐PD1‐based first‐line treatment of Hodgkin lymphoma

Published:2024-05-16 Issue:1 Volume:205 Page:22-24
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Bröckelmann Paul J.¹²³^ORCID

Affiliation:

1. Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD) University of Cologne Cologne Germany

2. German Hodgkin Study Group (GHSG) Cologne Germany

3. Max Planck Research Group Mechanisms of DNA Repair Max Planck Institute for Biology of Ageing Cologne Germany

Abstract

Anti‐PD1‐based first‐line treatment holds great promise in classical Hodgkin lymphoma. The management of immune‐related adverse events in the context of time‐limited combined checkpoint blockade and chemotherapy administered in curative intent is a challenge. Kuczmarski and Lynch provide a case‐based approach to key toxicities observed in this setting.Commentary on: Kuczmarski et al. Managing common toxicities associated with checkpoint inhibitor and chemotherapy combinations for untreated classic Hodgkin lymphoma. Br J Haematol 2024;205:100–108.

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.19534

Reference11 articles.

1. Managing common toxicities associated with checkpoint inhibitor and chemotherapy combinations for untreated classic Hodgkin lymphoma;Kuczmarski TM;Br J Haematol,2024

2. Durable Remissions in Advanced Stage and Molecularly High Risk Untreated Classic Hodgkin Lymphoma with Pembrolizumab + AVD

3. Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial

4. Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study

5. Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma